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~Ac id  stable amylolytic enzymes and lipase as components of 
pancreatic enzyme replacement in Cystic Fibrosis 
S. Scharp~ 1 , A.M. Lambeir 1 , M. Van Caillie-Bertrand 1 , L. Van Schil 1 , S. Van 
Biervliet 2, E. Robberecht 2. 1 Unic~ of Antwerp,2610 Wilrijk; 2Unic~ HosT., Ghent, 
Belgium 
Difficulties of pancreas enzyme substitution are known in CF notwithstanding the 
intake of sometimes high doses. For the digestion in the duodenum, the acid gastric 
content must be brought by means of pancreatic bicarbonate oa considerably higher 
pH value, because the pH optimum of pancreatic enzymes i  situated in the range 
between 6 and 9. In pancreatic insufficiency, shortage of bicarbonate impairs this 
neutralisation of pH. Postprandial duodenal pH may remain under a pH of 5 and 
can reduce the performance of the pancreatin therapy on several ways: (1) pancreas 
lipase and amylase are irreversibly inactivated at pH4; (2) bile salt precipitatin. 
(3) enzymes from pancreatin are too far from their respective pH optima; (4) enteric 
coated pancreatin may dissolve too late while the absorption of nutrients chiefly 
takes place in the first part of the duodenum-jejunum. Screening of a large variety 
of microorganisms resolved a source of Aspergillus niger amylase capable to resist 
acid treatment (pH 2.5, 37°C, 30 rain) and was selected for biochemical nd clinical 
characterisation. The selection of an appropriate replacement of human lipases is 
not only to be focused on activity and stability in function of pH but also on 
a compatible isomeric specificity. Lipases from Aspergillus niger and Rhizopus 
javanicus were found to restrict lipolytic activity to primary ester linkages (similar 
to human pancreas lipase) and to be stable in a broad pH zone. Since the Aspergillus 
niger source was found to be lower in lipolytic activity compared to Rhizopus 
javanicus, the last was selected for further characterisation a d clinical evaluation 
in function of therapeutic substitution in poor responders. 
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Aim: Monitoring and adjusting dose requirements of pancreatic enzyme replace- 
ment therapy (PERT) are an integral part of the dietetic assessment of patients 
with CE We wished to characterize enzyme usage in our adult clinic population 
and determine the extent o which inappropriate enzyme usage contributed to poor 
nutritional and clinical state. 
Method: Information was collected using a self-administered questionnaire devel- 
oped to measure patient practice, knowledge and beliefs relating to PERT. Using 
a blinded process, this information was mapped against measures of nutritional 
and clinical state. Exclusion criteria included pancreatic sufficiency, <1500 units 
lipase/kg/d, and FEV1 < 30%. 
Results: 49 out of potential clinic population of 72 patients completed the ques- 
tionnaire (16 54y, 55% male, FEV1 31 125%). Gender, marital status and age 
made no difference to how enzymes were taken. 67% of participants reported to 
never miss enzymes with meals, this was considerably lower for snacks (35%). 
Those patients who omit enzymes with meals also missed enzymes with snacks 
(r2 30%, p <0.001). There was no correlation between FEV1 and frequency of 
missed enzymes. A more appropriate use of PERT was observed in patients with 
lower as opposed to higher BMI. 
Conclusion: These results suggest greater dietetic involvement in underweight 
patients with whom enzyme use was more optimal. Patients of a normal BMI 
may have less incentive to adhere to PERT. Such attempts o better understand the 
factors associated with inappropriate PERT usage and its consequences challenges 
many of the presumptions that underlie this aspect of clinical care. 
• Immuno-Reactive Trypsinogen (IRT) reflects pancreatic status in 
CF and non-CF adults 
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Introduction; Newborn screening for CF is performed by measuring immunore- 
active trypsinogen (IRT) on the standard newborn heelprick test (with mutational 
analysis as a second-line test). There is good normal data for newborns, but little 
data about he normal range of IRT in non-CF adults, the effect of food or alcohol, 
and measures in pancreatic-sufficient (PS) and insufficient (PI) CF patients. 
Aims: to establish the normal range of IRT in healthy adults and to measure IRT 
in PS and PI CF adults. 
Methods: Whole blood was collected on standard newborn screening cards and 
IRT measured using AutoDELFIA, as for the newborn screening programme. 
Initial validation data was generated on 6 normal subjects with repeated measures 
throughout the day, before and after food and alcohol (10 g). Following this, a cohort 
of healthy volunteers was recruited with 15 20 individuals in the following groups: 
20 29, 30 39, 40 49, 50 59, 60 69, 70+. CF adults (PS&PI) undergoing annual 
review were recruited from the CF clinic. 
Results; IRT was constant through the day, unchanged by food or alcohol. The 
normal range in the total cohort was 10 24 gg/1 whole blood, with a gradual increase 
in IRT with each decade. As expected, normal-high IRT levels were found in the 
PS-CF and low levels in the PI-CF patients. 
Conclusion; This data supports the use of finger-prick IRT to assess pancreatic 
status in CF adults. This may also prove useful in the diagnostic workup of mild 
cases of CE 
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The majority of CF patients are pancreatic insufficient by the perinatal 
period.10 15% are pancreatic sufficient for a variable time period and a subgroup 
develop symptomatic chronic pancreatitis. The Royal Brompton CF database of 
adult patients (>16 yrs, 1986~004) was searched to identify all with symptomatic 
pancreatitis. 15 (1.5%)of 1012 patients were identified; 8 females and 7 males. The 
mean age at presentation with pancreatitis was 27 years (range 12 53).All presented 
with characteristic pain and imaging (6 had elevated amylase). 14/15 (93%)were 
pancreatic sufficient at the time of presentation.Of the 9 patients with both genes 
identified all carried a class IV or V mutation. There was a median of 3 hospital 
admissions (range 1 10) with symptomatic pancreatitis(median hospital stay 16 
days (range 7 65 days)). A specific complication occurred in 2 cases: bile duct 
obstruction i  one and a 5 cm pseudocyst in a second. A 3rd case developed pan- 
creatic ancer 23 years after a single episode ofpancreatitis. Pancreatic nsufficiency 
developed in 11 (73%) at a mean of 6 years after presentation (range 0 23 years) 
and coincided with pain resolution. 7 (47%) had gallstones. 2 had common bile 
duct stones and underwent endoscopic clearance. 3 had pancreatic stones managed 
endoscopically with pancreatic duct stenting and lithotripsy. In one case bile duct 
stenting was required. 5 underwent cholecystectomy. Symptomatic chronic pancre- 
atitis is a significant problem in a small group of patients with CF, most with class IV 
and V mutations. In most cases this occurs as pancreatic nsufficiency develops and 
an expectant approach is appropriate. Complex pancreato-biliary intervention may 
be required with close co-operation between specialist hepatobiliary and CF centres. 
